Table II.
Antitumor activity and body weight changes in mice implanted with human colorectal tumor HCT116 after treatment with TAS-102 and bevacizumab.
| Group | Dose (mg/kg) | Schedule | RTVa (mean ± SD) | TGIb (%) | RTV5c (days) | BWCd
|
|
|---|---|---|---|---|---|---|---|
| (Mean ± SD, g) | (%) | ||||||
| Control | – | – | 20.32±2.04 | 0 | 12.81±1.06 | 0.6±1.9- | 2.2 |
| TAS-102 | 150 | Day 1–14 (b.i.d.) | 7.60±0.90e | 62.6 | 23.24±1.41g | −1.4±2.2 NS | −5.6 |
| Bevacizumab | 5 | Day 1, 4, 8, 11 | 13.97±1.43e | 31.3 | 17.32±1.17g | 1.3±0.5 NS | 4.9 |
| Combination | 150+5 | 4.66±0.58e,f | 77.1 | >28.57g,h | −0.2±1.6 NS | −0.8 | |
a
Relative tumor volume on day 29;
b
Tumor growth inhibition ratio on day 29;
c
The period, RTV reaches 5;
d
Body weight change from day 0 to day 29; Each group consists of 6 mice;
e
P<0.001 vs. control using the two-sided Aspin Welch t-test;
f
P<0.001 by closed testing procedure using the two-sided Aspin-Welch t-test;
g
P<0.001 vs. control using the log-rank test;
h
P<0.001 vs. either monotherapy using the log-rank test; NS vs. control using the two-sided Aspin-Welch t-test; BWC, body weight change; RTV, relative tumor volume; TGI, tumor growth inhibition; NS, not significant.